An injection campaign would not have been so easy without Johnson’s vaccine

It was a disappointment this week. The first Johnson vaccines may have already been given to health workers. Instead, 80,000 vaccines are in the freezer, awaiting further investigation by US and European pharmaceutical companies. What is the probability that the Jansen vaccine will no longer be used in the Netherlands, or will only be used by people over the age of 60, such as AstraZeneca?

First, much less is known about Johnson’s side effect than AstraZeneca. Six cases are known, while seven million injections have been taken with Johnson in the United States. This means that the chance of this side effect now seems to be less than 1 in 1 million. If that number stays the same, the risk is certainly greater than the benefits: the cove is very dangerous.

But: it started with a few cases in AstraZeneca. There are 222 of the more than 34 million injections in Europe and the United Kingdom. Still a small chance (1 in 150,000), but bigger than Johnson. The question is whether Johnson’s figures follow AstraZeneca.

Large areas of color

What would the Netherlands do if it considered considering removing Johnson from the vaccine program based on new figures? Large brown areas of color give an idea of ​​the impact on the maps shown by Jab van Diesel on Wednesday in the House of Representatives. The head of the OMT showed which area of ​​the population is being vaccinated with which substance.

Under current planning, the majority of people in their forties will get their way from Johnson, followed by one-third in their thirties and twenties. Pfizer is available for another area. What is missing is that all those 60-year-olds will have to wait for deliveries from Pfizer.

There was good news for the pharmaceutical company: the Netherlands will already receive 1.9 million additional vaccines in the short term. The vaccines were promised earlier this week, but on Friday Pfizer announced that NOS would be available from the end of April instead of the end of June. With two injections per person, they are good for almost 1 million Dutch people.

The delay is less dramatic

That’s not enough to fill a gap left by Johnson. Johnson will deliver three million vaccines to the Netherlands this quarter. Since only one injection is needed in Johnson, that injection represents three million Dutch people. Health Minister Hugo de Jong said earlier this week that if Johnson left, it would mark a six-week delay in the vaccination program, adding that he was not yet aware that Pfizer would be accelerated with additional vaccinations. The delay may change less dramatically with additional deliveries. Suppose we are four weeks late, how bad is that?

For those over 60 who have not received Johnson, vaccinations may continue as planned. Younger groups may have to wait, but they are less likely to end up in the hospital and die less frequently if the cow.

That may be the case, says Marjolin von Ekmond, a professor of immunology, but all 60 juveniles die from gout: so far almost five hundred people have been infected with RIVM. “In addition, 10 percent of victims receive chronic coma, and they have long-term severe complaints,” says Van Ekmond. So a four-week delay means: more deaths, more hospitalizations, more chronic illness.

Dutch people under the age of 60 also play a major role in the spread of the virus. So Kovit will continue to be in circulation until they are mostly vaccinated. According to Van Ekmond, the cabinet’s relaxation plans could lead to further delays. It weighs in when the Netherlands have to make a decision about Johnson.

Johnson was an alternative to the younger groups

One of the main reasons the Health Council advised people over the age of 60 to book AstraZeneca was because there was an alternative to younger groups at the time: Johnson. Now there is no such thing: Pfizer’s additional distributions only partially solve the problem.

According to Van Ekmond, this means that the Health Council’s judgment on Johnson must be different from that of AstraZeneca, and Johnson’s side effect occurs equally frequently. Von Ekmond says: “I can not imagine that we will not use Johnson anymore.

This would certainly apply if the chance of side effects with Johnson was currently smaller than estimated. “As a healthy person over the age of 40, I have a 1 in 5000 chance of dying if I suffer from goiter,” says Van Ekmond. “I immediately choose to be vaccinated with one vaccine, which can cause more than 1 million in 1 million side effects. After good information, you can choose people.”

Also read:

It is not a big surprise why the rare side effects of the Johnson vaccine

AstraZeneca and Jansen vaccines are very common, but it does not explain exactly where the side effects come from. ‘Until we know the algorithm, it’s one thing to look at the coffee grounds.’

See also  Frank Ostdam: AC / DC | Flight News

Leave a Reply

Your email address will not be published. Required fields are marked *